Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Racemic nicotine is a synthetic form of nicotine composed of equal parts of the two enantiomers, S-nicotine and R-nicotine (50% each). Unlike natural tobacco-derived nicotine, which is almost exclusively the S-enantiomer, racemic nicotine is produced via chemical synthesis and contains both stereoisomers. The pharmacological activity of S-nicotine is significantly higher than that of R-nicotine; thus, products containing racemic mixtures may have different potency and effects compared to those with pure S-nicotine. Racemic synthetic nicotine acts as an agonist at nicotinic acetylcholine receptors throughout the nervous system, leading to stimulant effects such as increased alertness and reward signaling. It has been used in vaping products marketed as "tobacco-free" or "synthetic" alternatives[2][5][9]. The main mechanism involves stimulation of nicotinic-cholinergic receptors on autonomic ganglia, adrenal medulla, neuromuscular junctions, and in the brain[3][7]. Racemic synthetic nicotine is not derived from tobacco but manufactured through multi-step organic synthesis starting from precursors like ethyl nicotinate[5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on racemic nicotine.